SCHEMBL12810063

SCHEMBL12810063

COc1ccc2c(c1)OCC1c3ccccc3OC21

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.70
▸ MAPK1 P28482 1/20 0.70
▸ TDP1 Q9NUW8 1/20 0.70
▸ DRD2 P14416 2/20 0.55
▸ DRD3 P35462 2/20 0.55
▸ CYP19A1 P11511 2/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ MAOA P21397 2/20 0.44
▸ MAOB P27338 2/20 0.44
▸ HTR2A P28223 2/20 0.44
▸ HTR2C P28335 2/20 0.44
▸ USP2 O75604 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ ABCB1 P08183 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Homopterocarpin SCHEMBL31237481 0.93 MAPT (0.80) MAPTMAPK1TDP1DRD2DRD3
Homopterocarpin SCHEMBL12998414 0.93 MAPT (0.80) MAPTMAPK1TDP1DRD2DRD3
Homopterocarpin SCHEMBL12810250 0.93 MAPT (0.80) MAPTMAPK1TDP1DRD2DRD3
Homopterocarpin SCHEMBL12810803 0.93 MAPT (0.80) MAPTMAPK1TDP1DRD2DRD3
Homopterocarpin SCHEMBL29366996 0.93 MAPT (0.80) MAPTMAPK1TDP1DRD2DRD3
SCHEMBL18602053 0.86 MAPT (0.71) MAPTMAPK1TDP1DRD2DRD3
SCHEMBL12891389 0.86 MAPT (0.71) MAPTMAPK1TDP1DRD2DRD3
SCHEMBL12912390 0.85 MAPT (0.70) MAPTMAPK1TDP1DRD2DRD3
SCHEMBL19999732 0.85 MAPT (0.70) MAPTMAPK1TDP1DRD2DRD3
SCHEMBL72476 0.85 MAPT (0.70) MAPTMAPK1TDP1DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633203-B2 Use of pterocarpans as active anti-cellulite ingredients SYMRISE AG (DE) 2014-01-21 — — US disclosed
US-8633203-B2 Use of pterocarpans as active anti-cellulite ingredients SYMRISE AG (DE) 2014-01-21 — — US disclosed
EP-2295031-A2 Use of pterocarpans as anti-cellulite agents Symrise AG (DE) 2011-03-16 — — EP disclosed
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO., KG (DE) 2011-02-10 — — US disclosed
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS SYMRISE GMBH & CO., KG (DE) 2011-02-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034486-A1 USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS FABP4, PLIN1, CPT1B MAPT 4747/4885MAPK1 767/4885TDP1 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback